Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats

Experimental Biology and Medicine

Volumn 237, Issue 12, 2012, Pages 1402-1412

  Imig, John D ^a   Walsh, Katie A ^a   Khan, Md Abdul Hye ^a   Nagasawa, Tasuku ^a   Cherian Shaw, Mary ^a   Shaw, Sean M ^a   Hammock, Bruce D ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epoxyeicosatrienoic acid; Kidney; Metabolic syndrome

Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; 4 [4 [3 (1 ADAMANTYL) UREIDO] CYCLOHEXYLOXY] BENZOIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ALBUMIN; CD68 ANTIGEN; CHOLESTEROL; EPOXIDE HYDROLASE; FATTY ACID; LEPTIN; NEPHRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR FUNCTION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; HISTOLOGY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY INJURY; MESENTERIC ARTERY; METABOLIC SYNDROME X; NONHUMAN; OBESITY; RAT; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

ALBUMINURIA; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; EPOXIDE HYDROLASES; HYPERTENSION; HYPOGLYCEMIC AGENTS; KIDNEY GLOMERULUS; MACROPHAGES; MALE; OBESITY; PPAR GAMMA; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SPECIES SPECIFICITY; SYNDROME; THIAZOLIDINEDIONES;

EID: 84873045242     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2012.012225     Document Type: Article

References (58)

1. Lastra G, Manrique C, Sowers JR. Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence. Adv Chronic Kidney Dis 2006;13:365-73
2. Kirk EP, Klein S. Pathogenesis and pathophysiology of the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2009;11:761-5
3. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US Diabetes Care 2005;28:2745-9
4. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-7
5. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498-509
6. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003;144:2195-200
7. Knight SF, Quigley JE, Yuan J, Roy SS, Elmarakby A, Imig JD. Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. Hypertension 2008;51:352-9
8. Ochodnicky P, Vettoretti S, Henning RH, Buikema H, Van Dokkum RP, de Zeeuw D. Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. J Nephrol 2006;19:246-58
9. Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM, Zhang C. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res 2006;99:69-77
10. Elmarakby AA, Imig JD. Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. Clin Sci (Lond) 2010;118:291-301
11. Nishimatsu H, Suzuki E, Takeda R, Takahashi M, Oba S, Kimura K, Nagano T, Hirata Y. Blockade of endogenous proinflammatory cytokines ameliorates endothelial dysfunction in obese Zucker rats. Hypertens Res 2008;31:737-43
12. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 2004;25:331-6
13. Boden G, Cheung P, Mozzoli M, Fried SK. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism 2003;52:753-9
14. Fogo AB. PPARgamma and chronic kidney disease. Pediatr Nephrol 2010;26:347-51
15. Setti G, Hayward A, Dessapt C, Barone F, Buckingham R, White K, Bilous R, Hiroshi K, Gruden G, Viberti G, Gnudi L. Peroxisome proliferator-activated receptor-g agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes. Am J Nephrol 2010;32:393-402
16. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-35
17. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009;8:794-805
18. Luria A, Bettaieb A, Xi Y, Shieh GJ, Liu HC, Inoue H, Tsai HJ, Imig JD, Haj FG, Hammock BD. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci USA 2011;108:9038-43
19. Imig JD. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev 2006;24:169-88
20. Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev 2012;92:101-30
21. Zhao X, Dey A, Romanko OP, Stepp DW, Wang MH, Zhou Y, Jin L, Pollock JS, Webb RC, Imig JD. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2005;288:R188-96
22. Elmarakby AA, Faulkner J, Al-Shabrawey M, Wang MH, Maddipati KR, Imig JD. Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. Am J Physiol Regul Integr Comp Physiol 2011;301:R1307-17
23. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 2004;15:1244-53
24. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol 2009;297:F740-748
25. Tang WH, Maroo A. PPARg agonists: safety issues in heart failure. Diabetes Obes Metab 2007;9:447-54
26. Yang T, Soodvilai S. Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Res 2008;2008:1-8
27. Capdevila JH, Falck JR, Imig JD. Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney Intl 2007;72:683-9
28. Kalaitzidis RG, Sarafidis PA, Bakris GL. Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des 2009;15:529-36
29. Tolman KG. The safety of thiazolidinediones. Expert Opin Drug Saf 2011;10:419-28
30. Ernsberger P, Koletsky RJ, Kline DD, Bedol DM, Friedman JE. The SHROB model of syndrome X: effects of excess dietary sucrose. Ann N Y Acad Sci 1999;892:315-8
31. Khan O, Riazi S, Hu X, Song J, Wade JB, Ecelbarger CA. Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone. Am J Physiol Renal Physiol 2005;289:F442-450
32. Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999;48:1448-53
33. Ackerman Z, Oron-Herman M, Pappo O, Peleg E, Safadi R, Schmilovitz-Weiss H, Grozovski M. Hepatic effects of rosiglitazone in rats with the metabolic syndrome. Basic Clin Pharmacol Toxicol 2010;107:663-8
34. Chaput E, Saladin R, Silvestre M, Edgar AD. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun 2000;271:445-50
35. Burnham MP, Johnson IT, Weston AH. Reduced Ca2+-dependent activation of large-conductance Ca2+-activated K+ channels from arteries of Type 2 diabetic Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 2006;290:H1520-1527
36. Lu T, Wang XL, He T, Zhou W, Kaduce TL, Katusic ZS, Spector AA, Lee HC. Impaired arachidonic acid-mediated activation of large-conductance Ca2+-activated K+ channels in coronary arterial smooth muscle cells in Zucker Diabetic Fatty rats. Diabetes 2005;54:2155-63
37. Haddock RE, Grayson TH, Morris MJ, Howitt L, Chadha PS, Sandow SL. Diet-induced obesity impairs endothelium-derived hyperpolarization via altered potassium channel signaling mechanisms. PLoS One 2011;6:e16423
38. Hodnett BL, Xiang L, Dearman JA, Carter CB, Hester RL. K(ATP)-mediated vasodilation is impaired in obese Zucker rats. Microcirculation 2008;15:485-94
39. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2004;93:362-5
40. Irat AM, Aslamaci S, Karasu C, Ari N. Alteration of vascular reactivity in diabetic human mammary artery and the effects of thiazolidinediones. J Pharm Pharmacol 2006;58:1647-53
41. Mendizabal Y, Llorens S, Nava E. Reactivity of the aorta and mesenteric resistance arteries from the obese spontaneously hypertensive rat: effects of glitazones. Am J Physiol Heart Circ Physiol 2011;301:H1319-30
42. Mendizabal Y, Llorens S, Nava E. Effects of pioglitazone and rosiglitazone on vascular function of mesenteric resistance arteries in rat genetic hypertension. Pharmacology 2011;88:72-81
43. Lu X, Guo X, Karathanasis SK, Zimmerman KM, Onyia JE, Peterson RG, Kassab GS. Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats. Cardiovasc Diabetol 2010;9:19
44. Kinoshita H, Azma T, Iranami H, Nakahata K, Kimoto Y, Dojo M, Yuge O, Hatano Y. Synthetic peroxisome proliferator-activated receptor-gamma agonists restore impaired vasorelaxation via ATP-sensitive K+ channels by high glucose. J Pharmacol Exp Ther 2006;318:312-8
45. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997;100:1230-9
46. Mittermayer F, Schaller G, Pleiner J, Krzyzanowska K, Kapiotis S, Roden M, Wolzt M. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. J Clin Endocrinol Metab 2007;92:2574-80
47. Cindik N, Baskin E, Agras PI, Kinik ST, Turan M, Saatci U. Effect of obesity on inflammatory markers and renal functions. Acta Paediatr 2005;94:1732-7
48. Eardley KS, Zehnder D, Quinkler M, Lepenies J, Bates RL, Savage CO, Howie AJ, Adu D, Cockwell P. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int 2006;69:1189-97
49. Chow FY, Nikolic-Paterson DJ, Ma FY, Ozols E, Rollins BJ, Tesch GH. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007;50:471-80
50. Coimbra TM, Janssen U, Grone HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000;57:167-82
51. Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, Bank AJ. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med 2007;12:311-8
52. Ji Y, Liu J, Wang Z, Liu N, Gou W. PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab Invest 2009;89:887-902
53. Takano H, Hasegawa H, Zou Y, Komuro I. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des 2004;10:2779-86
54. Zafiriou S, Stanners SR, Saad S, Polhill TS, Poronnik P, Pollock CA. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol 2005;16:638-45
55. Iyer A, Kauter K, Alam MA, Hwang SH, Morisseau C, Hammock BD, Brown L. Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats. Exp Diabetes Res 2012;2012:ID758614
56. Pang W, Li N, Ai D, Niu XL, Guan YF, Zhu Y. Activation of peroxisome proliferator-activated receptor-gamma downregulates soluble epoxide hydrolase in cardiomyocytes. Clin Exp Pharmacol Physiol 2011;38:358-64
57. Imig JD. Eicosanoids and renal damage in cardiometabolic syndrome. Expert Opin Drug Metab Toxicol 2008;4:165-74
58. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, Shyy JY. The anti-inflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA 2005;102:16747-52